Yüklüyor......
Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
We determined whether the approved myelofibrosis drug ruxolitinib (Jakafi(®)), an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could be repurposed as an anti-cancer agent for solid tumors. Ruxolitinib synergistically interacted with dual ERBB1/2/4 inhibitors to kill breast as well as lung, ovaria...
Kaydedildi:
| Yayımlandı: | Front Oncol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4904019/ https://ncbi.nlm.nih.gov/pubmed/27379204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2016.00142 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|